Key Investor Signals
FDA meeting clarified Maman Port’s 510(k) pathway
Maman Biomedical completed its first FDA Pre-Submission meeting, aligning with reviewers on product classification, predicate family and required evidence.
Over $500,000 in non-dilutive funding secured
Maman Biomedical has secured over $500,000 in non-dilutive funding to support product development, regulatory work and commercialization.
Three patent families cover two microneedle formats
Maman Biomedical owns three patent families and has filed five US and Canadian applications covering hollow and dissolving microneedles.
Other Positive Signals
- Printed Maman Port on Formlabs production equipment while retaining target flow and mechanical performance.
- Won awards at the LevelUP and Lions Lair pitch competitions in 2024.
- Holds a six-month sponsored residency at Chicago’s mHUB, backed by Canada’s Trade Commissioner Service.
- Received early backing from Nventure’s DELIA fund for women-led ventures.
Team
Latchmi Raghunanan
CEO and Founder
- Led product development at Cohesys from 2019 to 2023 across bone-stabilization, hemostatic and dermal-filler programs with a cross-functional team of eight.
- Holds a PhD in materials science and is a named inventor on granted patents assigned to Trent University and Procter & Gamble.
- Worked as a Marie Curie postdoctoral fellow at Procter & Gamble in Brussels from 2016 to 2017 on bio-based adhesive chemistry.
Roopchand Raghunanan
CBO and Co-founder
- Served as Vice-President of Science and Technology at NIHERST, managing five division heads and a $6.4M project portfolio.
- Ran the Entrepreneur Success Initiative at Toronto Business Development Centre with a team of 10 and a $3.2M budget.
- Coordinated 12 European Development Fund capital projects worth $81M at CARICOM IMPACS and holds PMP and PgMP certifications.
Product
Maman Biomedical is developing three microneedle-based products for fertility treatment: a single-use device for existing injectable medicines, a dissolving patch for sustained delivery and an earlier-stage wearable concept for hormone monitoring.
Maman Port: hollow microneedle device
Maman Port is a single-use device designed to deliver the same prescribed fertility medication through the skin without a conventional hypodermic needle, allowing clinics to retain the existing drug and treatment protocol.
Maman Patch: dissolving delivery patch
Maman Patch uses drug-loaded dissolving microneedles designed for sustained hormone release. The company is developing it to reduce the number of daily injections required during part of a fertility-treatment cycle.
Maman Sense: wearable hormone monitor
Maman Sense is an earlier-stage wearable biosensor and companion-app concept designed to monitor hormone use through the skin and reduce repeated blood draws during fertility treatment.
Market Overview
A standard IVF cycle uses daily subcutaneous hormone injections to stimulate the ovaries and trigger egg release. Patients often administer more than 20 injections over roughly two weeks, creating a practical and emotional burden during an already demanding fertility-treatment process.
Fertility drugs are an established commercial category, with hormone medication used across assisted-reproduction cycles. Because treatment is often partly or fully self-funded, clinics have an incentive to improve patient experience without changing familiar medicines or treatment protocols.
The WHO estimated in 2023 that roughly one in six adults experience infertility during their lifetime.
CDC reported 435,426 assisted-reproduction cycles for 251,542 patients at 457 US clinics in 2022.
In a survey of 102 IVF patients, 19 said fear of needles had delayed their decision to start treatment.
Grand View Research projects the market to reach $5.6 billion by 2030, with 6.1% annual growth from 2023.
Comparable Outcomes
Antares Pharma
Antares Pharma developed self-injection devices that enabled patients to administer established medicines and licensed delivery platforms to pharmaceutical partners, alongside its own hormone products. Halozyme acquired Antares in May 2022 for $5.60 per share in cash, valuing the company at approximately $960 million.
Corium International
Corium developed transdermal delivery systems and MicroCor, a biodegradable microstructure platform designed to deliver small molecules and biologics through the skin. Gurnet Point Capital acquired Corium in 2018 for $12.50 per share in cash plus a $0.50 contingent value right, valuing it at up to $504 million.
Interested in More Startups Like Maman Biomedical?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.